ONI Reader Poll Online

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 5
Volume 16
Issue 5

Last month, ONI launched a new interactive feature: an electronic Reader Poll located on The Oncology Group website

MANHASSET, New York—Last month, ONI launched a new interactive feature: an electronic Reader Poll located on The Oncology Group website (www.cancernetwork.com). The poll question is keyed to an important article in each month's print issue.

In April, the poll question (at right) asked about possible ways to prevent the predicted shortage of oncologists in 2020. Of the more than 100 readers who voted, 41% said the best tactic is to increase the number of oncology fellowships. Increasing the use of nonphysician clinicians came in second at 23%, offering incentives to delay retirement was next at 15%, expanding the primary care physician's role for patients in remission garnered 14% of the vote, and improving health information technology (HIT) systems (to reduce paperwork) came in last at 7%.

Articles in this issue
Escalating Drug Costs Could Provoke Consumer Backlash
Androgen Deprivation Therapy Linked to Increased Cardiac Disease Mortality Risk
Large Study Casts Doubt on Value of CAD
Cetuximab Does Not Increase Mucositis in H&N Cancer
2004 Update Shows Continued Lower Breast Ca Incidence
Reclast Single-Dose Infusion Approved for Paget's Disease
Fragmin Approved for VTE in Cancer Pts
New Phase III Trial of Genasense in Advanced Melanoma Planned
Cervical Cancer Vaccines Show Sustained Protection
The 'New' Medicare: Passive Payer No More; PQRI Is First Step
ONI Reader Poll Online
EMRs Key to Optimized Reimbursement and Compliance With Quality Measures
Top 10 Outpatient Billing Errors, and How to Fix Them
IOM Urges Coordinated Approach to Biomarker Discovery
T-Cell Lymphoma Gets Its Own NCCN Treatment Guideline
Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content
Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma can now receive treatment with pirtobrutinib.

FDA Gives Accelerated Approval to Pirtobrutinib in CLL/SLL

December 1st 2023
Article

Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma can now receive treatment with pirtobrutinib.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

The FDA accepts the supplemental biologics license application for enfortumab vedotin-ejfv and pembrolizumab in patients with urothelial cancer following supporting data from the phase 3 KEYNOTE-A39 trial.

FDA Grants Priority Review for Pembrolizumab Combo in Bladder Cancer

December 1st 2023
Article

The FDA accepts the supplemental biologics license application for enfortumab vedotin-ejfv and pembrolizumab in patients with urothelial cancer following supporting data from the phase 3 KEYNOTE-A39 trial.

New treatment updates could help find more patient subtypes to target and treat in the world of CRC.

Multidisciplinary Care and New Treatment Options in CRC

November 20th 2023
Podcast

New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

CAR T-cell Therapy Remains Preferred Options for Relapsed/Refractory Multiple Myeloma

December 1st 2023
Article

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD.

Durvalumab/Tremelimumab/Surgery Appears Safe in Renal Cell Carcinoma

November 30th 2023
Article

Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD, PhD.